济南痛风脚肿可以拔火罐吗山东痛风有什么良方大全,山东怎样容易犯痛风,山东痛风的严重性会怎么样,济南痛风患者能吃莲子吗,山东痛风能吃叶酸品吗,济南痛风尿酸净胶囊 全连,济南痛风到医院挂哪个科室

THE HAGUE, June 1(Xinhua) -- Five people in the Netherlands have been sickened with an unusual strain of the E. coli bacteria, the institute for public health (RIVM) reported Wednesday.Of the five patients, four also suffered from intestinal problems and renal failure. The five who are infected all had recently been in Germany.The patients were infected with enterohaemorrhagic E.coli, or EHEC, a particularly deadly strain of the common bacteria found in the digestive systems of cows, humans and other mammals.The outbreak has hit at least eight European countries but virtually all of the sick people either live in Germany or recently traveled there.Medical authorities appeared no closer to discovering either the source of the infection or the mystery at the heart of the outbreak: why the unusual strain of the E. coli bacteria appears to be causing so many cases of hemolytic uremic syndrome, which attacks the kidneys and can cause seizures, strokes and comas.Earlier this week German researchers showed that Dutch cucumbers were not the cause of the contamination."It is essential to quickly find the source, as long as that is not found, the contamination can spread. It's a very aggressive bacteria and many people are seriously ill," a RIVM spokesman said.

BEIJING, Sept. 27 (Xinhuanet) -- People having a dog is way healthier than those don't, both physically and mentally, media reports said Tuesday.People owning dogs are more likely to take exercises than those having none, according to a recent poll of Mars Petcare, a pet food company.Two thirds of the walks dog owners take each week are attributed to their dogs, according to the poll, in which over 1,000 adults were surveyed.The survey also showed that 44 percent of dog owners over 65 years old make exercises because of their dogs.Dogs are a great motivator for doing exercises, said Dr. Sandra McCune, an animal behaviorist and also co-author of the book, "The Health Benefits of Dog Walking for People and Pets".

WASHINGTON, June 23 (Xinhua) -- NASA's next Mars rover has completed the journey from its California birthplace to Florida in preparation for launch this fall, the U.S. space agency said Thursday in a statement.The Mars Science Laboratory (MSL) rover, also known as Curiosity, arrived Wednesday at NASA's Kennedy Space Center aboard an Air Force C-17 transport plane. It was accompanied by the rocket-powered descent stage that will fly the rover during the final moments before landing on Mars.The rover's aeroshell -- the protective covering for the trip to the Red Planet -- and the cruise stage, which will guide it to Mars, arrived at Kennedy last month. The mission is targeted to launch from Cape Canaveral Air Force Station between Nov. 25 and Dec. 18. The car-size rover will land on Mars in August 2012.The rover and other spacecraft components will undergo more testing before mission staff stack them and fuel the onboard propulsion systems. Curiosity should be enclosed in its aeroshell for the final time in September and delivered to Kennedy's Launch Complex 41 in early November for integration with a United Launch Alliance Atlas V rocket.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm. During a prime mission lasting one Martian year -- nearly two Earth years -- researchers will use the rover's tools to study whether the landing region has had environmental conditions favorable for supporting microbial life and favorable for preserving clues about whether life existed.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, July 25 (Xinhuanet) -- More than one in three births in the U.S. are  delivered by C-section, which is an all time high and an increase of 25 percent over seven years, according to news reports Monday quoting a new study.Based on data from 19 states, C-section, or Cesarean, deliveries shot up from 27 percent of all births in 2002 to 34 percent in 2009, said the study by HealthGrades.  HealthGrades is an independent health care ratings organization with information on physicians, dentists and 5,000 hospitals in the nation.The study noted that the states with the highest rates are Texas, New Jersey and Florida while Utah, Colorado and Wisconsin are the lowest.Experts hold C-section deliveries are most suitable when vaginal delivery puts the health of the woman or child at risk, but also attributing the reason of increase to convenience, less risk, fertility and general attitudes.However, Divya Cantor, MD, MBA and HealthGrades Senior Physician Consultant. cautioned, "C-sections are rising, and there needs to be a little bit more scrutiny from the person who is having the C-section as well as doctors and hospitals."